XATMEP Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Xatmep, and what generic alternatives are available?
Xatmep is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug.
This drug has three patent family members in three countries.
The generic ingredient in XATMEP is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xatmep
A generic version of XATMEP was approved as methotrexate sodium by HIKMA on September 16th, 1986.
Summary for XATMEP
| International Patents: | 3 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,352 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XATMEP |
| What excipients (inactive ingredients) are in XATMEP? | XATMEP excipients list |
| DailyMed Link: | XATMEP at DailyMed |
Recent Clinical Trials for XATMEP
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
Pharmacology for XATMEP
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for XATMEP
US Patents and Regulatory Information for XATMEP
XATMEP is protected by seven US patents and two FDA Regulatory Exclusivities.
Patents protecting XATMEP
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methotrexate composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting XATMEP
TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN
Exclusivity Expiration: See Plans and Pricing
International Patents for XATMEP
See the table below for patents covering XATMEP around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2726524 | See Plans and Pricing | |
| European Patent Office | 2614814 | Composition de méthotrexate (Methotrexate composition) | See Plans and Pricing |
| United Kingdom | 201200192 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
